----item----
version: 1
id: {DFD2A801-318C-4EE3-8036-5E00AA101F37}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/14/Janssen to file daratumumab in 2015 on PhII data
parent: {C175FE23-2601-4F4F-B3CE-DA1791987470}
name: Janssen to file daratumumab in 2015 on PhII data
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 3cd61ce8-a866-40f8-9d87-4255f4e5673e

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 48

Janssen to file daratumumab in 2015 on PhII data
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 48

Janssen to file daratumumab in 2015 on PhII data
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2059

<p>Janssen (Johnson & Johnson) plans to submit a biologic licensing application to the US FDA and a marketing authorization application to the EMA this year for daratumumab in double refractory multiple myeloma. The submission will be based on Phase II data, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.</p><p>Daratumumab, licensed from Genmab, is one of 10 products that Janssen said it plans to file for regulatory approval between 2015 and 2019, "each with the potential to exceed $1bn in revenue," it told analysts during its pharmaceutical business review presentation on 20 May. In addition, it expects more than 40 line extensions of existing and new medicines.</p><p>Late-stage products expected to drive growth in the next several years, if regulatory approvals are secured, include daratumumab; sirukumab for rheumatoid arthritis; guselkumab for psoriasis; JNJ-927 (ARN-509) for pre-metastatic prostate cancer; imetelstat for myelofibrosis; JNJ-493 (FGFRi kinase inhibitor) for urothelial cancer; esketamine for treatment-resistant depression; AL-8176 for respiratory syncytial virus (RSV); fulranumab for osteoarthritic pain; JNJ-872 (VX-787) for influenza A; JNJ-922 (Orexin-2 antagonist) for primary insomnia; and AL-335 for hepatitis C. Daratumumab and esketamine have both received breakthrough therapy designations from the FDA.</p><p><b>Related stories</b></p><p><a href="http://www.scripintelligence.com/home/Celgene-drops-Morphosyss-daratumumab-chasing-anti-CD38-MAb-357522" target="_new">Celgene drops Morphosys's daratumumab-chasing anti-CD38 MAb</a></p><p><a href="http://www.scripintelligence.com/researchdevelopment/Genmab-rises-on-Phase-II-daratumumab-promise-in-double-refractory-myeloma-356537" target="_new">Genmab rises on Phase II daratumumab promise in double refractory myeloma</a></p><p><a href="http://www.scripintelligence.com/researchdevelopment/Janssen-takes-Genmabs-daratumumab-into-Phase-III-350393" target="_new">Janssen takes Genmab's daratumumab into Phase III</a></p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 356

<p>Janssen (Johnson & Johnson) plans to submit a biologic licensing application to the US FDA and a marketing authorization application to the EMA this year for daratumumab in double refractory multiple myeloma. The submission will be based on Phase II data, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 48

Janssen to file daratumumab in 2015 on PhII data
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150514T160001
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150514T160001
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150514T160001
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028774
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 48

Janssen to file daratumumab in 2015 on PhII data
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{20E0B55E-5592-4DBF-A9D4-58B471A17E67}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

headline news
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358425
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042349Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

3cd61ce8-a866-40f8-9d87-4255f4e5673e
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042349Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
